These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 1722373)

  • 1. [Serum acute phase proteins for determining disease activity of ulcerative colitis and Crohn disease].
    Vucelić B; Milicić D; Krznarić Z; Korać B; Sentić M; Hadzić N; Stavljenić A; Cvorisćec D
    Acta Med Austriaca; 1991; 18(4):100-5. PubMed ID: 1722373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of C-reactive protein in the evaluation of activity in ulcerative colitis and Crohn's disease].
    Vucelić B; Krznarić Z; Sentić M; Milicić D; Korać B; Cvorisćec D; Stavljenić A
    Lijec Vjesn; 1990; 112(9-10):281-4. PubMed ID: 2093781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
    Niederau C; Backmerhoff F; Schumacher B; Niederau C
    Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
    Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
    Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The usefulness of reactive protein C in managing patients with ulcerative colitis and Crohn's disease].
    López Morante AJ; Sáez-Royuela F; Yuguero del Moral L; Martín Lorente JL; Ojeda Giménez C
    Rev Esp Enferm Dig; 1993 Jan; 83(1):5-9. PubMed ID: 8452705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individual fecal alpha 1-antitrypsin excretion reflects clinical activity in Crohn's disease but not in ulcerative colitis.
    Becker K; Berger M; Niederau C; Frieling T
    Hepatogastroenterology; 1999; 46(28):2309-14. PubMed ID: 10521988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Qualitative study of fecal alpha-1-antitrypsin in patients with inflammatory digestive disease and patients with ileostomy].
    Colombel JF; Mizon C; Chekkouri N; Balduyck M; Chaussade S; Becuwe C; Degand P; Mizon J; Cortot A
    Gastroenterol Clin Biol; 1991; 15(4):301-5. PubMed ID: 2060740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Blood protein concentrations--are they parameters of disease activity in Crohn's disease?].
    Meryn S; Lochs H; Bettelheim P; Sertl K; Mulak K
    Leber Magen Darm; 1985 Jul; 15(4):160-4. PubMed ID: 3877229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal excretion of alpha 2-macroglobulin: a novel marker for disease activity in patients with inflammatory bowel disease.
    Becker K; Niederau C; Frieling T
    Z Gastroenterol; 1999 Jul; 37(7):597-605. PubMed ID: 10458008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low prevalence of anti-neutrophil cytoplasmic antibodies in ulcerative colitis patients with long-term remission.
    Lindgren S; Florén CH; Lindhagen T; Starck M; Stewenius J; Nässberger L
    Eur J Gastroenterol Hepatol; 1995 Jun; 7(6):563-8. PubMed ID: 7552641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease.
    Winterkamp S; Weidenhiller M; Otte P; Stolper J; Schwab D; Hahn EG; Raithel M
    Am J Gastroenterol; 2002 Dec; 97(12):3071-7. PubMed ID: 12492192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission.
    Valentini L; Schaper L; Buning C; Hengstermann S; Koernicke T; Tillinger W; Guglielmi FW; Norman K; Buhner S; Ockenga J; Pirlich M; Lochs H
    Nutrition; 2008; 24(7-8):694-702. PubMed ID: 18499398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.
    Folwaczny C; Wiebecke B; Loeschke K
    Am J Gastroenterol; 1999 Jun; 94(6):1551-5. PubMed ID: 10364024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships between clinical data and histology of the large bowel in Crohn's disease and ulcerative colitis.
    Schmitz-Moormann P; Himmelmann GW; Brandes JW
    Pathol Annu; 1985; 20 Pt 1():281-301. PubMed ID: 3991239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining disease activity in inflammatory bowel disease.
    Cooke WT; Prior P
    J Clin Gastroenterol; 1984 Feb; 6(1):17-25. PubMed ID: 6699391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total parenteral nutrition modifies the acute phase response to Crohn's disease.
    Carlson GL; Gray P; Barber D; Shaffer JL; Mughal M; Irving MH
    J R Coll Surg Edinb; 1994 Dec; 39(6):360-4. PubMed ID: 7532715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application of chosen granulocyte markers in diagnostics of Leśniowski-Crohn's disease and ulcerative colitis--preliminary research].
    Fedak D; Pawlica D; Ciećko-Michalska I; Solnica B; Mach T
    Przegl Lek; 2010; 67(2):114-8. PubMed ID: 20557011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma levels of endothelin-1 in patients with Crohn's disease and ulcerative colitis.
    Letizia C; Boirivant M; De Toma G; Cerci S; Subioli S; Scuro L; Ferrari P; Pallone F
    Ital J Gastroenterol Hepatol; 1998 Jun; 30(3):266-9. PubMed ID: 9759593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum inhibitors of leukocyte chemotaxis in Crohn's disease and ulcerative colitis.
    Rhodes JM; Potter BJ; Brown DJ; Jewell DP
    Gastroenterology; 1982 Jun; 82(6):1327-34. PubMed ID: 6978274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute phase proteins in acute pancreatitis].
    Dujmović F; Kulauzov M; Danicić B
    Med Pregl; 1998; 51(9-10):395-9. PubMed ID: 9863327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.